105 related articles for article (PubMed ID: 34706703)
1. Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
Sajjadi E; Venetis K; Piciotti R; Gambini D; Blundo C; Runza L; Ferrero S; Guerini-Rocco E; Fusco N
BMC Cancer; 2021 Oct; 21(1):1152. PubMed ID: 34706703
[TBL] [Abstract][Full Text] [Related]
2. Partial PTEN deletion is linked to poor prognosis in breast cancer.
Lebok P; Kopperschmidt V; Kluth M; Hube-Magg C; Özden C; B T; Hussein K; Mittenzwei A; Lebeau A; Witzel I; Wölber L; Mahner S; Jänicke F; Geist S; Paluchowski P; Wilke C; Heilenkötter U; Simon R; Sauter G; Terracciano L; Krech R; von d Assen A; Müller V; Burandt E
BMC Cancer; 2015 Dec; 15():963. PubMed ID: 26672755
[TBL] [Abstract][Full Text] [Related]
3. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
4. Mutation of PTEN: Loss and Likelihood of Being a Non-responder to Trastuzumab in a Sample of Iraqi Her2+ Breast Cancer Patients.
Hammadi AH; Ali SH
Cureus; 2024 Feb; 16(2):e54765. PubMed ID: 38524002
[TBL] [Abstract][Full Text] [Related]
5. Correction: The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-Analysis.
Yari K; Hakimi A; Mohammadi M; Ammari-Allahyari M; Salari N; Ghasemi H
Biochem Genet; 2024 Apr; ():. PubMed ID: 38658495
[No Abstract] [Full Text] [Related]
6. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Adams S; Othus M; Patel SP; Miller KD; Chugh R; Schuetze SM; Chamberlin MD; Haley BJ; Storniolo AMV; Reddy MP; Anderson SA; Zimmerman CT; O'Dea AP; Mirshahidi HR; Ahnert JR; Brescia FJ; Hahn O; Raymond JM; Biggs DD; Connolly RM; Sharon E; Korde LA; Gray RJ; Mayerson E; Plets M; Blanke CD; Chae YK; Kurzrock R
Clin Cancer Res; 2022 Jan; 28(2):271-278. PubMed ID: 34716198
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
[TBL] [Abstract][Full Text] [Related]
8. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
Hamada A; Suda K; Koga T; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Uchida T; Mitsudomi T
Lung Cancer; 2021 Dec; 162():79-85. PubMed ID: 34741886
[TBL] [Abstract][Full Text] [Related]
9. SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer.
Klaric KA; Riaz N; Asleh K; Wang XQ; Atalla T; Strickland S; Nielsen TO; Kos Z
Histopathology; 2022 Feb; 80(3):589-597. PubMed ID: 34725848
[TBL] [Abstract][Full Text] [Related]
10. The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status.
Shao J; Li J; Song L; He Q; Wu Y; Li L; Liu D; Wang C; Li W
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1550. PubMed ID: 34766737
[TBL] [Abstract][Full Text] [Related]
11. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
Wang C; Lin Y; Zhu H; Zhou Y; Mao F; Huang X; Zhou X; Cao X; Sun Q
Breast Cancer; 2022 Mar; 29(2):314-323. PubMed ID: 34766244
[TBL] [Abstract][Full Text] [Related]
12. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Suppan C; Graf R; Jahn S; Zhou Q; Klocker EV; Bartsch R; Terbuch A; Kashofer K; Regitnig P; Lindenmann J; Posch F; Gerritsmann H; Jost PJ; Heitzer E; Dandachi N; Balic M
Br J Cancer; 2022 Feb; 126(3):456-463. PubMed ID: 34754095
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
Zhang J; Wang Y; Liu Z; Wang L; Yao Y; Liu Y; Hao XZ; Wang J; Xing P; Li J
Thorac Cancer; 2021 Dec; 12(24):3407-3415. PubMed ID: 34751504
[TBL] [Abstract][Full Text] [Related]
14. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Liu SY; Bao H; Wang Q; Mao WM; Chen Y; Tong X; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Dong S; Zhang XC; Su J; Yang JJ; Yang XN; Zhou Q; Wu X; Shao Y; Zhong WZ; Wu YL
Nat Commun; 2021 Nov; 12(1):6450. PubMed ID: 34750392
[TBL] [Abstract][Full Text] [Related]
15. The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer.
Kang N; Kim KH; Jeong BH; Lee K; Kim H; Kwon OJ; Ahn MJ; Cho J; Lee HY; Um SW
Cancer Res Treat; 2022 Jul; 54(3):817-826. PubMed ID: 34749486
[TBL] [Abstract][Full Text] [Related]
16. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.
Bou-Dargham MJ; Draughon S; Cantrell V; Khamis ZI; Sang QA
J Cancer; 2021; 12(23):6949-6963. PubMed ID: 34729098
[TBL] [Abstract][Full Text] [Related]
17. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
Lehmann BD; Colaprico A; Silva TC; Chen J; An H; Ban Y; Huang H; Wang L; James JL; Balko JM; Gonzalez-Ericsson PI; Sanders ME; Zhang B; Pietenpol JA; Chen XS
Nat Commun; 2021 Nov; 12(1):6276. PubMed ID: 34725325
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities.
Lloyd MR; Spring LM; Bardia A; Wander SA
Clin Cancer Res; 2022 Mar; 28(5):821-830. PubMed ID: 34725098
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Analysis Identified Two Subtypes of Brain Tumor Characterized by Distinct Immune Infiltration and Prognosis.
Shen X; Wang X; Shen H; Feng M; Wu D; Yang Y; Li Y; Yang M; Ji W; Wang W; Zhang Q; Song F; Liu B; Chen K; Li X
Front Oncol; 2021; 11():734407. PubMed ID: 34722280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
